Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00130780
Status:
COMPLETED
Last Update Posted:
2016-01-25
First Post:
2005-08-12
Brief Title:
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer NSCLC - BEACON Study Bevacizumab and Chemotherapy for Operable NSCLC
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer NSCLC BEACON Study Bevacizumab and Chemotherapy for Operable NSCLC
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II single institution trial for patients with clinical Stage IB-IIIA NSCLC T1-3N0-2M0 who have resectable lung tumors The primary goal of this study is to show that the addition of bevacizumab to a cisplatin-based chemotherapy in the neoadjuvant setting for non-squamous cell carcinomas improves the rate of pathologic downstaging which correlates with survival Downstaging is defined as any decrease in the final pathologic stage compared with the clinical stage before induction therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None